Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

Background: Cladribine tablets have recently become available in The Netherlands for patients with relapsing–remitting multiple sclerosis (RRMS) as a disease-modifying agent that reduces the frequency and severity of relapses and delays disability progression. Objective: The aim of this study was to...

Full description

Bibliographic Details
Main Authors: Budhia, S. (Author), de Fransesco, M. (Author), Harty, G. (Author), Hengstman, G.J.D (Author), Krol, M. (Author), Mahajan, K. (Author), Michels, R.E (Author), Schiffers, K.M.H (Author)
Format: Article
Language:English
Published: Adis 2019
Subjects:
aciclovir
adult
Adult
alemtuzumab
Article
autoimmune thyroiditis
beta interferon
cladribine
Cladribine
clemastine
clinical outcome
cohort analysis
comparative effectiveness
controlled study
cost benefit analysis
cost effectiveness analysis
cost utility analysis
Cost-Benefit Analysis
disease activity
disease severity
drug cost
drug efficacy
drug hypersensitivity
drug safety
economics
Expanded Disability Status Scale
female
Female
fingolimod
flu like syndrome
gastrointestinal disease
glatiramer
health status
human
Humans
idiopathic thrombocytopenic purpura
immunosuppressive agent
Immunosuppressive Agents
infection
infusion related reaction
injection site reaction
macular edema
major clinical study
male
Male
malignant neoplasm
Markov chain
Markov Chains
methylprednisolone
money
multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting
natalizumab
Netherlands
network meta-analysis
paracetamol
phase 3 clinical trial (topic)
placebo
progressive multifocal leukoencephalopathy
quality adjusted life year
Quality-Adjusted Life Years
sensitivity analysis
tablet
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items